Terns Pharmaceuticals, Inc. (TERN) Research

Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to advancing novel small-molecule treatments. Its primary focus lies in developing both standalone agents and combination therapies to address non-alcoholic steatohepatitis (NASH) and obesity. The company's pipeline includes several key drug candidates: TERN-101, a farnesoid X receptor agonist distinguished by its liver-specific distribution and non-bile acid properties, is presently undergoing Phase IIa clinical trials for NASH. TERN-201, a vascular adhesion protein-1 inhibitor, is in Phase Ib clinical studies, also targeting NASH. Terns is also progressing TERN-501, a thyroid hormone receptor beta agonist engineered for improved liver targeting and metabolic resilience, through Phase I clinical trials for NASH. Furthermore, the company is advancing TERN-601, an oral small-molecule Glucagon-Like Peptide-1 receptor agonist program, intended for the management of NASH and various metabolic conditions, including obesity. Established in 2016, Terns Pharmaceuticals maintains its corporate headquarters in Foster City, California.

Market snapshot

Symbol
TERN
Price
$52.95
Day change
-0.03%
Market cap
$4.8B
P/E ratio
-51.28x
52-week range
2.655-53.19
Sector
Healthcare
Industry
Biotechnology
Analyst price target
$55.50

Recent news

  • Merck Lowered Terns Pharmaceuticals Offer Price After Trial Data Review

    The deal consideration is $53.00 per share in cash for an approximate equity value of $6.7 billion.

  • Nasdaq, Dow Jones finish session ahead, oil price softens as US pushes for Iran peace talks

    4:15pm: In the green US stocks finished Wednesday’s session higher on hopes peace talks will soon resolve the US-Iran conflict. The Nasdaq was up 0.8% at...

  • Merck's $6.7 Billion Terns Pharmaceuticals Acquisition May Face Rival Interest: Analyst

    The deal consideration is $53.00 per share in cash for an approximate equity value of $6.7 billion.

Peer companies

  • Amylyx Pharmaceuticals, Inc. (AMLX)
  • Enliven Therapeutics, Inc. (ELVN)
  • Immatics N.V. (IMTX)
  • Inhibrx Biosciences, Inc. (INBX)
  • Nektar Therapeutics (NKTR)
  • ORIC Pharmaceuticals, Inc. (ORIC)
  • Precigen, Inc. (PGEN)
  • Relay Therapeutics, Inc. (RLAY)

Recent insider activity

  • Azelby Robert — D-Return (90000 shares) on 2026-05-05
  • Azelby Robert — D-Return (1697 shares) on 2026-05-05
  • Turner Heather D — D-Return (45000 shares) on 2026-05-05
  • Turner Heather D — D-Return (64000 shares) on 2026-05-05
  • Turner Heather D — D-Return (1697 shares) on 2026-05-05

Open Terns Pharmaceuticals, Inc. (TERN) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.